Huntington’s Disease, a cruel genetic curse that robs individuals of control over their own bodies, has long remained a therapeutic enigma. Recently, CUHK researchers may have unlocked a critical piece of the puzzle. By identifying PAPD5 as a key culprit in neuronal damage and showcasing the potential of the BCH001 inhibitor, they are opening a promising new chapter in the fight against this devastating condition.